Development of immunotherapeutic strategies for the treatment of malignant neoplasms

James E. Talmadge

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Focused preclinical studies have been used to gain insight into the mechanism of therapeutic activity of cytokines, growth factors and biological response modifiers (BRMs). These data can then be used to develop a clinical hypothesis to facilitate the development of these new biological drugs. In this manuscript, we discuss a number of preclinical and clinical studies using interferon-γ, IL-2, and the colony stimulating factors. The importance of the systematic profiling of the biological activity of such biological drugs is emphasized and we discuss the utility of the mechanistic data in their clinical development. The overall preclinical approach identifies the cellular, biochemical or gene regulatory event that is associated with the therapeutic activity of a biologic and this surrogate (be it biological, chemical, or quality of life) is then used to optimize the clinical protocol in a phase lb trial. This, in theory, results in the rapid identification of the optimal dose, schedule and route of administration for subsequent testing in a phase II/III clinical trial.

Original languageEnglish (US)
Pages (from-to)215-236
Number of pages22
Issue number3
StatePublished - Mar 1992


  • Biological Response Modifiers (BRMs)
  • colony stimulating factor granulocyte-macrophage (CSF-GM)
  • colony stimulating factor-granulocyte (CSF-G)
  • immunotherapy and immunopharmacology
  • interferon (IFN)
  • interferon-γ (IFN-γ)
  • interleukin-2 (IL-2)
  • metastasis

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Development of immunotherapeutic strategies for the treatment of malignant neoplasms'. Together they form a unique fingerprint.

Cite this